MedTrace Logo

Impact of Tiotropium Add-on Therapy in Patients With Asthma

NCT03964220 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7857

Last updated 2020-11-03

Study results available
· View outcomes & findings →

Summary

To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy

Conditions

Interventions

DRUG

Tiotropium Respimat®

Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )

DRUG

Inhaled Corticosteroid/Long-acting beta-agonist

baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA

Sponsors & Collaborators

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-15
Primary Completion
2019-09-20
Completion
2019-09-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03964220 on ClinicalTrials.gov